John Ryan
Managing Director & Partner @ ONSET Ventures
Denver, United States
John Ryan is a Series C investor at ONSET Ventures in Denver focused on Health Care and Medical. John Ryan is the chief legal officer for Level 3 Communications. He is responsible for Level 3’s legal and regulatory functions worldwide.Mr. Ryan has worked in roles supporting Level 3’s customer contracting and vendor contracting since 1999 and led Level 3’s public policy group from 2005 until 2010. Prior to his tenure at Level 3, Mr. Ryanwas an associate and partner at the Fraser Stryker law firm in Omaha, Neb., where his practice focused on the communications industry.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 11%
Last updated:
For AI agents: llms.txt
Industries John Ryan invests in
Stages John Ryan invests in
Countries John Ryan invests in
Investment Focus
Industry
- Health Care 5 (56%)
- Medical 4 (44%)
- Biotechnology 4 (44%)
- Medical Device 3 (33%)
- Diabetes 1 (11%)
Stage
- Series C 3 (33%)
- Series D 3 (33%)
- Series B 1 (11%)
- Series E 1 (11%)
- Funding Round 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Vertos Medical
|
Vertos Medical is a healthcare company that offers medical devices used in the treatment of common spinal diseases. The company commercializes the percutaneous treatment for lumbar spinal stenosis (LSS). It also offers minimally invasive lumbar decompression devices for the treatment of various forms of LSS. The company offers its devices in theUnited States. Vertos Medical was founded by Dr. Dave Solsberg and Dr. Don Schomer in 2005 and is headquartered in Aliso Viejo, California. | $28M / Jun 12, 2017 | |
Valeritas
|
Valeritas is a medical technology company committed to developing and commercializing innovative drug delivery solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes. Valeritas' medical technologies portfolio is headlined by the h-Patch technology. The first use of theh-Patch technology will be the V-Go disposable insulin delivery device for continuous delivery both at a preset basal rate and for on-demand bolus dosing at mealtimes.The V-Go is a simple-to-use, once-daily, disposable insulin delivery device that provides a preset basal rate and on-demand bolus dosing for mealtime coverage via a mealtime insulin. The V-Go will enable the millions suffering from Type 2 diabetes to conveniently and discreetly deliver insulin throughout the day bolus dose on-demand around mealtimes.The h-Patch technology is also being developed to serve as a launching platform for applications across a wide spectrum of medical needs. | $45M / Series D / Jul 11, 2014 | |
Relievant Medsystems
|
Relievant's mission is to provide patients with low risk therapy that can alleviate their back pain. | $30M / Series D / Mar 28, 2012 | |
|
Valeritas
|
Valeritas is a medical technology company committed to developing and commercializing innovative drug delivery solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes. Valeritas' medical technologies portfolio is headlined by the h-Patch technology. The first use of theh-Patch technology will be the V-Go disposable insulin delivery device for continuous delivery both at a preset basal rate and for on-demand bolus dosing at mealtimes.The V-Go is a simple-to-use, once-daily, disposable insulin delivery device that provides a preset basal rate and on-demand bolus dosing for mealtime coverage via a mealtime insulin. The V-Go will enable the millions suffering from Type 2 diabetes to conveniently and discreetly deliver insulin throughout the day bolus dose on-demand around mealtimes.The h-Patch technology is also being developed to serve as a launching platform for applications across a wide spectrum of medical needs. | $150M / Series C / Sep 12, 2011 | |
PowerVision
|
PowerVision is a private company focused on developing a novel accommodating intraocular lens, which is designed to restore True AccommodationTM. Their innovative FluidVisionTM accommodating intraocular lens (IOL) is poised to help individuals affected by presbyopia and/or cataracts regain the ability to dynamically adjust focus for clearvision at all distances.Fifty years ago, vision correction surgery was changed forever by the invention of the intraocular lens, which is used to treat a cataract – a clouding and hardening of the dime-sized, normally clear, crystalline lens inside your eye which can rob you of your vision in your 60’s, 70’s and 80’s.PowerVision set out to dramatically improve vision correction surgery again. They began the development of their FluidVision IOL, which mimics the way a healthy eye works and can restore clear vision at all distances, near, far, and everywhere in between. It uses a tiny amount of fluid inside the lens and natural eye muscles to change shape and adjust focus just the way your healthy eye does.For the more than 20 million people with cataracts in the U.S. and, ultimately, the more than 90 million with Presbyopia – the loss of ability to focus up close that affects people in their 40’s and 50’s – the FluidVision lens can potentially give them freedom from ever needing glasses, contacts or any vision correction procedure again. | $24M / Series C / Jul 15, 2011 | |
VisionCare Ophthalmic Technologies
|
VisionCare Ophthalmic Technologies, Inc., a Saratoga, CA-based developer of advanced visual prosthetic devices designed to improve vision in patients with end-stage age-related macular degeneration (AMD).VisionCare Ophthalmic Technologies (VisionCare) is a privately held specialty medical device company engaged in the research, development,manufacture, and marketing of proprietary implantable ophthalmic devices and technologies that are intended to significantly improve vision and quality of life for individuals with untreatable retinal disorders.Our lead product, the Implantable Miniature Telescope (by Dr. Isaac Lipshitz), is the first FDA-approved implantable medical device demonstrated to improve vision and quality of life in individuals with the most advanced, irreversible form of age-related macular degeneration (AMD) – End-Stage AMD. End-Stage AMD is the leading cause of blindness in older Americans.The telescope implant is integral to the CentraSight™ treatment program which has been developed to help patients follow the necessary steps for proper diagnosis, surgical evaluation, and postoperative care.Our goal is to help patients reconnect to the things in life they love to see and do. To help achieve this, we will establish a high level of collaboration with our healthcare provider customers through a broad range of direct support programs and services. | $31M / Series E / Jan 10, 2011 | |
|
Vertos Medical
|
Vertos Medical is a healthcare company that offers medical devices used in the treatment of common spinal diseases. The company commercializes the percutaneous treatment for lumbar spinal stenosis (LSS). It also offers minimally invasive lumbar decompression devices for the treatment of various forms of LSS. The company offers its devices in theUnited States. Vertos Medical was founded by Dr. Dave Solsberg and Dr. Don Schomer in 2005 and is headquartered in Aliso Viejo, California. | $15.5M / Series D / Oct 20, 2009 | |
|
Relievant Medsystems
|
Relievant's mission is to provide patients with low risk therapy that can alleviate their back pain. | $20M / Series C / Jul 07, 2009 | |
|
Relievant Medsystems
|
Relievant's mission is to provide patients with low risk therapy that can alleviate their back pain. | $5.1M / Series B / Oct 22, 2006 |
Co-Investors
About ONSET Ventures
ONSET Ventures is a private equity firm that offers early- and later-stage investment services to firms in the IT and medical technology industries. It was founded by David Kelley, Michael Levinthal, and Terry Opdendyk and is based in California.
ONSET Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Robert Kuhling
General Partner and Managing Director
|
|||
Shomit Ghose
General Partner
|
|||
Beatrice Pezino
CFO
|
|||
Jennifer Lewis
Vice President of Marketing & Communications
|
|||
|
John Ryan
Managing Director & Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does John Ryan invest in?
John Ryan invests primarily in Health Care, Medical and Biotechnology startups, most often at Series C and Series D stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did John Ryan last invest?
The most recent investment recorded for John Ryan closed in Jun 2017. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
